Chapter 9. Does Intensive Glycaemic Management Reduce Morbidity and Mortality in Type 1 Diabetes?

  1. William H. Herman1,
  2. Ann Louise Kinmonth2,
  3. Nicholas J. Wareham3 and
  4. Rhys Williams4
  1. William H. Herman

Published Online: 12 JAN 2010

DOI: 10.1002/9780470682807.ch9

The Evidence Base for Diabetes Care, Second Edition

The Evidence Base for Diabetes Care, Second Edition

How to Cite

Herman, W. H. (2010) Does Intensive Glycaemic Management Reduce Morbidity and Mortality in Type 1 Diabetes?, in The Evidence Base for Diabetes Care, Second Edition (eds W. H. Herman, A. L. Kinmonth, N. J. Wareham and R. Williams), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470682807.ch9

Editor Information

  1. 1

    Department of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI, USA

  2. 2

    General Practice and Primary Care Research Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

  3. 3

    MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK

  4. 4

    School of Medicine, Swansea University, Swansea, UK

Author Information

  1. Department of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI, USA

Publication History

  1. Published Online: 12 JAN 2010
  2. Published Print: 19 FEB 2010

ISBN Information

Print ISBN: 9780470032749

Online ISBN: 9780470682807

SEARCH

Keywords:

  • intensive glycaemic management and reducing morbidity and mortality in type 1 diabetes;
  • intensive glycaemic management on microvascular and neuropathic complications;
  • ‘glucose hypothesis’ - complications of diabetes to chronic hyperglycaemia;
  • Stockholm Diabetes Intervention Study (SDIS);
  • Diabetes Control and Complications Trial (DCCT) - confirmed and extended findings;
  • Microalbuminuria Collaborative Study Group - 70 type 1 diabetic patients with microalbuminuria;
  • intensive glycaemic management benefits - cardiovascular disease and survival;
  • randomized controlled trials of intensive insulin therapy (IIT) in type 1 diabetes;
  • association between hyperglycaemia and type 1 diabetes mortality;
  • type 1 diabetes microvascular complications and ‘metabolic memory’

Summary

This chapter contains sections titled:

  • Introduction

  • The benefits of intensive glycaemic management on microvascular and neuropathic complications

  • The benefits of intensive glycaemic management: cardiovascular disease and survival

  • Metabolic memory

  • The risks of intensive glycaemic management

  • The target for intensive glycaemic management

  • References